US533A - Truss for hermta - Google Patents
Truss for hermta Download PDFInfo
- Publication number
- US533A US533A US533DA US533A US 533 A US533 A US 533A US 533D A US533D A US 533DA US 533 A US533 A US 533A
- Authority
- US
- United States
- Prior art keywords
- pad
- band
- post
- inch
- mortises
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002184 metal Substances 0.000 description 14
- 229910000831 Steel Inorganic materials 0.000 description 4
- 239000010959 steel Substances 0.000 description 4
- 101700065560 andI Proteins 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F5/00—Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices; Anti-rape devices
- A61F5/01—Orthopaedic devices, e.g. splints, casts or braces
- A61F5/24—Trusses
- A61F5/26—Trusses with belt springs
Definitions
- the hinge and brace self adjusting truss consists of a steel vcurved band A bent and hardened with a spring temper so that the spring will extend to suit the size of the body, and extend a little more than half way around the body of the patient
- this curved band is square sides and flat and half of an inch wide where the two mortises B C pass through which is about one inch from the end from the mortises to the end it tapers in width and thickness and rises about one quarter of an inch, with the end turned over as at D to admit a link7 E holding its width where the mo-rtises pass through about one inch then tapering down to three eighths of an inch and holding that width to the end, and is about one eighth of an inch thick where the mortises pass through about one inch, then gradually tapering two inches to half an eighth and continues that thickness within one inch from the back end and tapering a little and turned over to admit a link, the oval pad F hereafter described is attached to the spring band by the mortise through the band standing about twenty degrees out from
- the strap M is attached to a metal link nearest to the oval pad with a steel wire spring N attached to it and strap to the other end to pass through a buckle the other end of the band, the strap is secured to the band by a metal link and the end of the strap a buckle O to take up or let out to suitthe size of the patient.
- the invention claimed by me, the said JosIAH I-IUNGEREORD, and which I desire to secure by Letters Patent consists in The particular mode described of reversing the pad by means of the oblique mortises, and of constructing the post I-I, the brace I, and their appendages, for connecting" the pad to the spring and adjusting it in its place.
Landscapes
- Health & Medical Sciences (AREA)
- Nursing (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
Description
UNITED sTATEs PATENT oEEioE.
JOSIAH HUNGERFORD, OF DOVER, NEI/V YORK.
TRUSS FOR HERNIA.
Specication of Letters Patent No. 533i, dated December 26, 1837.
To all whom t may concern Be it known that I, IosIAH IIUNGEREORD, of Dover, in the county of Duchess and State of New York, have invented a new and useful Improvement in Trusses; and I do hereby declare that the following is a full and eXact description; andI to enable others skilled in the art to make and use my invention I will proceed to describe its construction and operation, and have also illustrated it by the accompanying drawings.
The hinge and brace self adjusting truss consists of a steel vcurved band A bent and hardened with a spring temper so that the spring will extend to suit the size of the body, and extend a little more than half way around the body of the patient this curved band is square sides and flat and half of an inch wide where the two mortises B C pass through which is about one inch from the end from the mortises to the end it tapers in width and thickness and rises about one quarter of an inch, with the end turned over as at D to admit a link7 E holding its width where the mo-rtises pass through about one inch then tapering down to three eighths of an inch and holding that width to the end, and is about one eighth of an inch thick where the mortises pass through about one inch, then gradually tapering two inches to half an eighth and continues that thickness within one inch from the back end and tapering a little and turned over to admit a link, the oval pad F hereafter described is attached to the spring band by the mortise through the band standing about twenty degrees out from the center line of the band one on each side of the center so that the pad can be reversed on either side to suit the rupture on the patient leaving the shape between the two mortises like the letter V, the rupture pad is metal and of an oval form on the back and upper focus of which is a post of metal with a hole through near the lower end through which passes a staple which connects the post H with the pad the lower end of the post round in such a manner as to admit the post to incline lengthwise of the pad either way from a perpendicular about five degrees with a rounding on each side of the bottom of the-post fork the band to rest on giving the pad a chance for a rotary motion in the spring band, this post connects the pad to the band by inserting through either oft the mortises inthe band setting the lower end of thepad in an angle to suit the patient, the mortises vbeing longer on the outside so the post can turn either way to adjust the pad so that it shall have an equal and uniform pressure on the rupture on the end of the post thatA projects through the band is a groove with a hole through for a pin to hold the brace I the brace is metal and attached to the pad by a staple J passing through one end of the brace down to the lower focus of the pad leaving the otheil end room to lift up and down, the other end of the brace sits down in the groove of the post the brace having four or five holes in that end so that the pin that passes through the post and through either of the holes to suit the patient and adjust the pad, the back pad K is round and of metal and is attached to the back part of the band by a clasp L so that it can be moved either way to suit the size of the pa-V tient and secured by a metal wedge'` to its proper place. The strap M is attached to a metal link nearest to the oval pad with a steel wire spring N attached to it and strap to the other end to pass through a buckle the other end of the band, the strap is secured to the band by a metal link and the end of the strap a buckle O to take up or let out to suitthe size of the patient. Y
The invention claimed by me, the said JosIAH I-IUNGEREORD, and which I desire to secure by Letters Patent consists in The particular mode described of reversing the pad by means of the oblique mortises, and of constructing the post I-I, the brace I, and their appendages, for connecting" the pad to the spring and adjusting it in its place.
JOSIAH HUNGERFORD.
Witnesses:
JOHN WING, JACOB WING.'
Publications (1)
Publication Number | Publication Date |
---|---|
US533A true US533A (en) | 1837-12-26 |
Family
ID=2060812
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US533D Expired - Lifetime US533A (en) | Truss for hermta |
Country Status (1)
Country | Link |
---|---|
US (1) | US533A (en) |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050177171A1 (en) * | 2002-02-13 | 2005-08-11 | Merrick Wetzler | Surgical drill guide |
WO2010031790A1 (en) | 2008-09-17 | 2010-03-25 | Basf Se | Devices and method for continuous distillative separation of a mixture containing one or more alkanolamine(s) |
WO2013174432A1 (en) | 2012-05-24 | 2013-11-28 | Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) | Method for the identification of the origin of a cancer of unknown primary origin by methylation analysis |
EP2687202A1 (en) | 2009-07-31 | 2014-01-22 | F. Hoffmann-La Roche AG | Subcutaneous anti-her2 antibody formulation |
WO2018160841A1 (en) | 2017-03-01 | 2018-09-07 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
WO2020163589A1 (en) | 2019-02-08 | 2020-08-13 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
EP3698807A1 (en) | 2005-01-21 | 2020-08-26 | Genentech, Inc. | Fixed dosing of her antibodies |
WO2020226986A2 (en) | 2019-05-03 | 2020-11-12 | Genentech, Inc. | Methods of treating cancer with an anti-pd-l1 antibody |
WO2021062085A1 (en) | 2019-09-27 | 2021-04-01 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
WO2021083949A1 (en) | 2019-10-29 | 2021-05-06 | F. Hoffmann-La Roche Ag | Bifunctional compounds for the treatment of cancer |
WO2021097110A1 (en) | 2019-11-13 | 2021-05-20 | Genentech, Inc. | Therapeutic compounds and methods of use |
WO2021127404A1 (en) | 2019-12-20 | 2021-06-24 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
EP3862630A1 (en) | 2020-02-04 | 2021-08-11 | Dongguan Yih Teh Electric Products Co., Ltd | Aroma diffuser and fragrance capsule |
WO2021250284A1 (en) | 2020-06-12 | 2021-12-16 | Eligo Bioscience | Specific decolonization of antibiotic resistant bacteria for prophylactic purposes |
WO2021257503A1 (en) | 2020-06-16 | 2021-12-23 | Genentech, Inc. | Methods and compositions for treating triple-negative breast cancer |
WO2022020716A1 (en) | 2020-07-24 | 2022-01-27 | Genentech, Inc. | Heterocyclic inhibitors of tead for treating cancer |
WO2022036146A1 (en) | 2020-08-12 | 2022-02-17 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
WO2022076462A1 (en) | 2020-10-05 | 2022-04-14 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2022133345A1 (en) | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
WO2022171745A1 (en) | 2021-02-12 | 2022-08-18 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydroazepine derivatives for the treatment of cancer |
EP4067347A1 (en) | 2016-05-24 | 2022-10-05 | Genentech, Inc. | Heterocyclic inhibitors of cbp/ep300 for the treatment of cancer |
WO2022251296A1 (en) | 2021-05-25 | 2022-12-01 | Erasca, Inc. | Sulfur-containing heteroaromatic tricyclic kras inhibitors |
WO2022266206A1 (en) | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Kras inhibitor conjugates |
EP4119583A1 (en) | 2008-01-30 | 2023-01-18 | Genentech, Inc. | Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof |
EP4155415A1 (en) | 2016-02-29 | 2023-03-29 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
WO2023097195A1 (en) | 2021-11-24 | 2023-06-01 | Genentech, Inc. | Therapeutic indazole compounds and methods of use in the treatment of cancer |
EP4249917A2 (en) | 2018-09-21 | 2023-09-27 | F. Hoffmann-La Roche AG | Diagnostic methods for triple-negative breast cancer |
WO2023191816A1 (en) | 2022-04-01 | 2023-10-05 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024015897A1 (en) | 2022-07-13 | 2024-01-18 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024013723A1 (en) | 2022-07-15 | 2024-01-18 | Pheon Therapeutics Ltd | Antibody drug conjugates that bind cdcp1 and uses thereof |
WO2024033457A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
WO2024033389A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
EP4335931A2 (en) | 2015-05-29 | 2024-03-13 | F. Hoffmann-La Roche AG | Therapeutic and diagnostic methods for cancer |
WO2024091991A1 (en) | 2022-10-25 | 2024-05-02 | Genentech, Inc. | Therapeutic and diagnostic methods for multiple myeloma |
-
0
- US US533D patent/US533A/en not_active Expired - Lifetime
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050177171A1 (en) * | 2002-02-13 | 2005-08-11 | Merrick Wetzler | Surgical drill guide |
EP3698807A1 (en) | 2005-01-21 | 2020-08-26 | Genentech, Inc. | Fixed dosing of her antibodies |
EP4119583A1 (en) | 2008-01-30 | 2023-01-18 | Genentech, Inc. | Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof |
WO2010031790A1 (en) | 2008-09-17 | 2010-03-25 | Basf Se | Devices and method for continuous distillative separation of a mixture containing one or more alkanolamine(s) |
EP2687202A1 (en) | 2009-07-31 | 2014-01-22 | F. Hoffmann-La Roche AG | Subcutaneous anti-her2 antibody formulation |
EP4339212A2 (en) | 2009-07-31 | 2024-03-20 | F. Hoffmann-La Roche AG | Subcutaneous anti-her2 antibody formulation |
WO2013174432A1 (en) | 2012-05-24 | 2013-11-28 | Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) | Method for the identification of the origin of a cancer of unknown primary origin by methylation analysis |
EP4335931A2 (en) | 2015-05-29 | 2024-03-13 | F. Hoffmann-La Roche AG | Therapeutic and diagnostic methods for cancer |
EP4155415A1 (en) | 2016-02-29 | 2023-03-29 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
EP4067347A1 (en) | 2016-05-24 | 2022-10-05 | Genentech, Inc. | Heterocyclic inhibitors of cbp/ep300 for the treatment of cancer |
WO2018160841A1 (en) | 2017-03-01 | 2018-09-07 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
EP4249917A2 (en) | 2018-09-21 | 2023-09-27 | F. Hoffmann-La Roche AG | Diagnostic methods for triple-negative breast cancer |
WO2020163589A1 (en) | 2019-02-08 | 2020-08-13 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
WO2020226986A2 (en) | 2019-05-03 | 2020-11-12 | Genentech, Inc. | Methods of treating cancer with an anti-pd-l1 antibody |
WO2021062085A1 (en) | 2019-09-27 | 2021-04-01 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
WO2021083949A1 (en) | 2019-10-29 | 2021-05-06 | F. Hoffmann-La Roche Ag | Bifunctional compounds for the treatment of cancer |
WO2021097110A1 (en) | 2019-11-13 | 2021-05-20 | Genentech, Inc. | Therapeutic compounds and methods of use |
WO2021127404A1 (en) | 2019-12-20 | 2021-06-24 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
EP3862630A1 (en) | 2020-02-04 | 2021-08-11 | Dongguan Yih Teh Electric Products Co., Ltd | Aroma diffuser and fragrance capsule |
WO2021250284A1 (en) | 2020-06-12 | 2021-12-16 | Eligo Bioscience | Specific decolonization of antibiotic resistant bacteria for prophylactic purposes |
WO2021257503A1 (en) | 2020-06-16 | 2021-12-23 | Genentech, Inc. | Methods and compositions for treating triple-negative breast cancer |
WO2022020716A1 (en) | 2020-07-24 | 2022-01-27 | Genentech, Inc. | Heterocyclic inhibitors of tead for treating cancer |
WO2022036146A1 (en) | 2020-08-12 | 2022-02-17 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
WO2022076462A1 (en) | 2020-10-05 | 2022-04-14 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2022133345A1 (en) | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
WO2022171745A1 (en) | 2021-02-12 | 2022-08-18 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydroazepine derivatives for the treatment of cancer |
WO2022251296A1 (en) | 2021-05-25 | 2022-12-01 | Erasca, Inc. | Sulfur-containing heteroaromatic tricyclic kras inhibitors |
WO2022266206A1 (en) | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Kras inhibitor conjugates |
WO2023097195A1 (en) | 2021-11-24 | 2023-06-01 | Genentech, Inc. | Therapeutic indazole compounds and methods of use in the treatment of cancer |
WO2023191816A1 (en) | 2022-04-01 | 2023-10-05 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024015897A1 (en) | 2022-07-13 | 2024-01-18 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024013723A1 (en) | 2022-07-15 | 2024-01-18 | Pheon Therapeutics Ltd | Antibody drug conjugates that bind cdcp1 and uses thereof |
WO2024033457A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
WO2024033389A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
WO2024091991A1 (en) | 2022-10-25 | 2024-05-02 | Genentech, Inc. | Therapeutic and diagnostic methods for multiple myeloma |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US533A (en) | Truss for hermta | |
US872A (en) | Hand-bellows | |
US41548A (en) | Improvement in machines for treating curved spines | |
US2829A (en) | Tettss | |
US181699A (en) | Improvement in wrenches | |
USD3913S (en) | Design for burial caskets | |
US3571A (en) | Epenetus a | |
US390951A (en) | Hitching-post | |
US53017A (en) | Improvement in buckles | |
US3814A (en) | Improvement in grain-cradles | |
US119233A (en) | Improvement in trusses | |
US200612A (en) | Improvement in buck-saw frames | |
US52745A (en) | Andeew eakkin | |
USRE4697E (en) | Improvement in trusses | |
US79991A (en) | Improved teuss-pad | |
US70683A (en) | Charles a | |
US292547A (en) | James dockstadeb | |
US177340A (en) | Improvement in fence-posts | |
US113623A (en) | Improvement in shawl-straps | |
US146332A (en) | Improvement in bridge-trusses | |
US1226A (en) | Tbttss fob the cube of hernia | |
US3812A (en) | Truss | |
US65520A (en) | Geoege e | |
US1165A (en) | Stibrup fob saddles | |
US55724A (en) | Improvement in trusses |